Publications by authors named "Maria Poza"

Claim this Profile
E
Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma.
María Poza, Alejandro Martin-Muñoz, Patricia López-Pereira, Gloria Figaredo, Irene Zamanillo

Cancers (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.
Mariana Bastos-Oreiro, Pau Abrisqueta, Antonio Gutierrez, Ana Jiménez Ubieto, Maria Poza

Hemasphere· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Ana Jiménez-Ubieto, Alejandro Martín-Muñoz, María Poza, Sara Dorado, Almudena García-Ortiz

Front Immunol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease.
Gloria Figaredo, Alejandro Martín-Muñoz, Santiago Barrio, Laura Parrilla, Yolanda Campos-Martín, María Poza

Cancers (Basel)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Ana Jiménez-Ubieto, Alejandro Martín-Muñoz, María Poza, Sara Dorado, Almudena García-Ortiz

Front Immunol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Ana Jiménez-Ubieto, Alejandro Martín-Muñoz, María Poza, Sara Dorado, Almudena García-Ortiz

Front Immunol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of IPSS-M implementation in real-life clinical practice.
Irene Zamanillo, Maria Poza, Rosa Ayala, Inmaculada Rapado, Joaquín Martinez-Lopez

Front Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT.
Ana Jiménez-Ubieto, María Poza, Alejandro Martin-Muñoz, Yanira Ruiz-Heredia, Sara Dorado

Leukemia· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A programme for early diagnosis of atrial fibrillation: a multi-centre study in primary care.
Javier D Cabrera, Guillem Fluxà, Carmen Fuentes, Jordi Hoyo, Marta Navarro, María Amparo de la Poza

Fam Pract· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology.
Noemí Álvarez, Alba Rodríguez-García, María Luz Morales, Miguel Gutiérrez, Marta Montero, María Poza

Leuk Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Joaquin Martinez-Lopez, Rafael Alonso, Sandy W Wong, Rafael Rios, Nina Shah, Maria Poza

J Hematol Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia.
María Poza, Rodrigo Íñiguez, Irene Zamanillo, Sara Redondo, Rafael Alonso

Ther Adv Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.
Carolina Villegas, María Poza, Paloma Talayero, José Manuel Caro Teller, Denis Zafra

Ann Hematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies.
José María Sanchez-Pina, Mario Rodríguez Rodriguez, Nerea Castro Quismondo, Rodrigo Gil Manso, Rafael Colmenares, María Poza

Eur J Haematol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis